已发表论文

晚期非小细胞肺癌中国患者的治疗:针对埃克替尼用药治疗

 

Authors Liang JL, Ren XC, Lin Q

Published Date May 2014 Volume 2014:7 Pages 761—770

DOI http://dx.doi.org/10.2147/OTT.S49233

Received 14 March 2014, Accepted 8 April 2014, Published 16 May 2014

Abstract: Icotinib hydrochloride is an orally administered small-molecule reversible tyrosine kinase inhibitor that has been independently researched and developed and has independent intellectual property rights in the People’s Republic of China. Clinical trials have demonstrated that the response to icotinib among advanced non-small-cell lung cancer (NSCLC) patients who received at least one platinum-based chemotherapy regimen was not inferior to gefitinib. Since being launched August 2011 in the People’s Republic of China, icotinib has been widely used in clinics, and has become an important treatment option for Chinese patients with advanced NSCLC. The present study presents the Phase I, II, and III clinical trials of icotinib and discusses current clinical applications in the People’s Republic of China and future research directions.
Keywords: targeted therapy, EGFR-TKI, NSCLC